Mylan Pharma Takes On Boehringer’s Mirapex Patent

Law360, New York (December 14, 2005, 12:00 AM EST) -- Mylan Pharmaceuticals Inc. is seeking to challenge German drug maker Boehringer Ingelheim International Gmbh for market share of Parkinson’s disease drug Mirapex. That challenge prompted a federal lawsuit in which Mylan will try to invalidate the drug’s patents.

Boehringer’s complaint, filed in conjunction with its Connecticut-based subsidiary, was brought in the U.S. District Court for the District of Delaware.

The lawsuit came on the heels of Mylan’s Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration, which seeks approval to manufacture and market...
To view the full article, register now.